Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has earned a consensus recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $6.53.
A number of brokerages have recently weighed in on ADAP. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 1st. BidaskClub cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 22nd. Finally, Leerink Swann cut shares of Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 price objective for the company. in a research report on Tuesday.
A number of hedge funds have recently added to or reduced their stakes in ADAP. SG Americas Securities LLC increased its position in Adaptimmune Therapeutics by 157.3% during the 4th quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 12,229 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Adaptimmune Therapeutics by 8.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,621 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 2,280 shares in the last quarter. Raymond James & Associates increased its position in Adaptimmune Therapeutics by 31.8% during the 1st quarter. Raymond James & Associates now owns 30,185 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 7,279 shares in the last quarter. Henry James International Management Inc. acquired a new position in Adaptimmune Therapeutics during the 4th quarter worth approximately $144,000. Finally, B. Riley Wealth Management Inc. acquired a new position in Adaptimmune Therapeutics in the 3rd quarter valued at approximately $148,000. Institutional investors and hedge funds own 65.96% of the company’s stock.
Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 43.60%. On average, research analysts forecast that Adaptimmune Therapeutics will post -1.24 earnings per share for the current year.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Read More: Analyst Ratings Trading
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.